title: Preclinical in vivo evaluation of an extracorporeal HIFU device for ablation of pancreatic tumors.
abstract: Extracorporeal high-intensity focused ultrasound (HIFU) can be used to ablate tissue noninvasively by delivering focused ultrasound energy from an external source. HIFU for clinical treatment of pancreatic cancer has been reported; however, systematic evaluation of the safety and efficacy of pancreatic ablation with HIFU has not been performed. The objectives of this in vivo study are as follows: (1) assess the safety and feasibility of targeting and ablating pancreatic tissue using the FEP-BY02 HIFU system (Yuande Bio-Medical Engineering, Beijing, China); (2) evaluate a method for estimating in situ acoustic treatment energy in an in vivo setting; and (3) identify the optimal treatment parameters that result in safe and effective ablation of the pancreas. The pancreata of 12 common swine were treated in vivo. Prior to therapy, blood was drawn for laboratory analysis. Animals were then treated with extracorporeal HIFU at three different acoustic treatment energies (750, 1000 and 1250 J). Endoscopy was performed prior to and immediately following HIFU therapy to assess for gastric injury. Blood was drawn after completion of the treatment and on days 2 and 7 following treatment to assess for biochemical evidence of pancreatitis. Animals were then euthanized 7 d following treatment and a necropsy was performed to assess for unintended injury and to obtain pancreatic tissue for histology to assess efficacy of HIFU ablation. Histologic scoring of pancreatic tissue changes was performed by a pathologist blinded to the treatment energy delivered. The degree of ablation identified on histology correlated with the treatment energy. No collateral tissue damage was seen at treatment energies of 750 and 1000 J. At 1250 J, thermal injury to the abdominal muscles and gastric ulcers were observed. There were no premature deaths, serious illnesses, skin burns or evidence of pancreatitis on biochemical analysis. HIFU treatment of the pancreas is feasible, safe and can be used to ablate tissue noninvasively. A clinical trial in humans examining the use of extracorporeal HIFU for palliation of pain related to pancreatic cancer is planned.
authors.affiliation: Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA, USA. jooha@u.washington.edu
authors.forename: Joo Ha
authors.initials: JH
authors.lastname: Hwang
authors.forename: Yak-Nam
authors.initials: YN
authors.lastname: Wang
authors.forename: Cinderella
authors.initials: C
authors.lastname: Warren
authors.forename: Melissa P
authors.initials: MP
authors.lastname: Upton
authors.forename: Frank
authors.initials: F
authors.lastname: Starr
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Zhou
authors.forename: Stuart B
authors.initials: SB
authors.lastname: Mitchell
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005240:Feasibility Studies; D010179:Pancreas / Q000000981:diagnostic imaging / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000628:therapy*; D034421:Sus scrofa; D014464:Ultrasonic Therapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D014463:Ultrasonography